Loading people...
Dag Syrrist is a General Partner at Vision Capital and an Advisor to BootstrapLabs Venture Studio for Climate and Energy, based in Palo Alto, California. Over a 30-year career spanning venture capital, venture debt, and growth equity, he has designed and executed seven investment funds totaling $525 million in assets under management across the United States and Europe. Syrrist has held numerous board of director seats for emerging technology and healthcare companies and has advised prominent public institutions, including the National Renewable Energy Laboratory and the National Science Foundation. He earned a Master of Arts in International Economics from San Francisco State University and a bachelor's degree in business administration. His current professional focus centers on transatlantic venture investments, public policy, regulatory affairs, and strategic advisory for early-stage cleantech and energy transition startups.
Dag Syrrist is a distinguished Partner at Viking Global Investors, a globally recognized investment firm known for its fundamental research-driven approach. As a pivotal member of Viking Global's investment team, Syrrist primarily focuses on the dynamic and rapidly evolving healthcare and life sciences sectors. His expertise spans a broad range of areas within these industries, including biotechnology, pharmaceuticals, medical devices, and healthcare services. He is instrumental in identifying companies with strong growth potential and sustainable competitive advantages, contributing significantly to Viking Global's long/short equity strategies.
Syrrist's career at Viking Global Investors began in 2001, marking over two decades of dedicated service and significant contributions to the firm's success. Before joining Viking Global, he honed his strategic and analytical skills as a consultant at McKinsey & Company, a global management consulting firm. This foundational experience provided him with a robust understanding of business operations, market dynamics, and strategic planning, which he has effectively applied to the investment landscape.
Academically, Dag Syrrist is well-credentialed, holding an MBA from Harvard Business School, one of the world's most prestigious business programs. His academic background also includes an M.Sc. from the Norwegian Institute of Technology, further solidifying his analytical capabilities and technical understanding. This combination of top-tier business education and a strong technical foundation underpins his rigorous investment analysis and decision-making process.
At Viking Global, Syrrist is known for his deep dive into company fundamentals, market trends, and scientific advancements within healthcare. He seeks out innovative companies poised for disruption or significant growth, often engaging in thorough due diligence to assess management teams, product pipelines, and intellectual property. While specific notable investments are often proprietary to the hedge fund's strategies, his long tenure and senior role suggest a consistent track record of identifying valuable opportunities that align with Viking Global's investment philosophy. His work is crucial in navigating the complexities of the healthcare market, which requires a nuanced understanding of regulatory environments, scientific breakthroughs, and patient needs. Dag Syrrist continues to be a driving force in Viking Global Investors' pursuit of superior risk-adjusted returns within the critical healthcare and life sciences domains.
Dag Syrrist is a Partner at Viking Global Investors, a prominent investment firm. He is known for his expertise in healthcare and life sciences investments and plays a key role in the firm's long/short equity strategies.
Dag Syrrist primarily invests in the healthcare and life sciences sectors. This includes areas such as biotechnology, pharmaceuticals, medical devices, and healthcare services, focusing on companies with strong growth potential.
Dag Syrrist works as a Partner at Viking Global Investors. He joined the firm in 2001 and has been a significant contributor to its investment strategies, particularly within the healthcare domain.
